— Know what they know.
Not Investment Advice
Also trades as: 0K16.L (LSE) · $vol 0M

EOLS NASDAQ

Evolus, Inc.
1W: -10.4% 1M: -21.2% 3M: +2.1% YTD: +6.2% 1Y: +16.1% 3Y: -21.4% 5Y: -9.3%
$7.14
-0.55 (-7.15%)
 
Weekly Expected Move ±6.8%
$6 $7 $7 $8 $8
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 37 · $470.2M mcap · 50M float · 1.70% daily turnover · Short 67% of daily vol

📊 Key Metrics

TTM
$316M
Revenue
+13.9% YoY
$-34M
Net Income
+44.6% YoY
$-20M
Free Cash Flow
+56.8% YoY
68.0%
Gross Margin
-5.4%
Op. Margin
-9.6%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE138.6%
ROA-14.4%
ROIC-20.7%

Valuation

P/E-13.8
P/B-15.2
EV/EBITDA-56.4

Leverage

Debt/Equity-5.33
Current Ratio1.70
Interest Cov.-1.1x

Quality Scores

Piotroski F5/9
Altman Z-1.48
Beneish M-2.59

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms